发明公开
- 专利标题： CYANOTRIAZOLE COMPOUNDS
-
申请号： EP23155266.2申请日： 2014-07-16
-
公开(公告)号： EP4219477A1公开(公告)日： 2023-08-02
- 发明人: Sato, Seiji , Matsuda, Satoshi , Matsumura, Chiharu , Itotani, Motohiro , Shinohara, Toshio , Fujita, Shigekazu , Sakurai, Yohji , Tai, Kuninori , Fukushima, Tae , Kanemoto, Naohide , Okamoto, Takashi
- 申请人： Otsuka Pharmaceutical Co., Ltd.
- 申请人地址： JP Tokyo 101-8535 2-9, Kanda Tsukasa-machi Chiyoda-ku
- 代理机构： dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB
- 优先权： US201461928267 P 20140116
- 主分类号： C07D403/12
- IPC分类号： C07D403/12 ; C07D401/14 ; C07D405/14 ; C07D413/14 ; C07D401/12 ; C07D403/14 ; C07D405/12 ; C07D411/12 ; C07D411/14 ; C07D413/12 ; C07D417/12 ; C07D417/14 ; C07D249/04 ; C07D249/06 ; A61K31/4192 ; A61P3/00 ; A61P9/00
摘要：
This invention relates to a cyanotriazole compound represented by the formula (1):
wherein each symbols are defined in the specification,
or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.
wherein each symbols are defined in the specification,
or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.
信息查询
